Common infections measured by clinical assessment over 28 months · primary progressive multiple sclerosis
Rituximab as 'first choice' showed no clear difference in common infections measured by clinical assessment over 28 months compared with placebo (low certainty).
1 finding from 1 review
Cancer · primary progressive multiple sclerosis
Rituximab as 'first choice' showed no clear difference in cancer measured by clinical assessment over 28 months compared with placebo (low certainty).
1 finding from 1 review
Mortality measured by clinical assessment over 12 months · primary progressive multiple sclerosis
Rituximab as 'first choice' showed no clear difference in mortality measured by clinical assessment over 28 months compared with placebo (low certainty).
1 finding from 1 review
Clinical relapse · relapsing multiple sclerosis
Rituximab as 'switching' may leads to lower relapse measured by clinical assessment over 12 months compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events measured by clinical assessment over 12 months · relapsing multiple sclerosis
It is very uncertain whether rituximab as 'switching' changes serious adverse events measured by clinical assessment over 12 months compared with placebo (very low certainty).
1 finding from 1 review
Common infections measured by clinical assessment over 12 months · relapsing multiple sclerosis
It is very uncertain whether rituximab as 'switching' changes common infections measured by clinical assessment over 12 months compared with placebo (very low certainty).
1 finding from 1 review
Cancer · relapsing multiple sclerosis
It is very uncertain whether rituximab as 'switching' changes cancer measured by clinical assessment over 12 months compared with placebo (very low certainty).
1 finding from 1 review
Mortality measured by clinical assessment over 12 months · relapsing multiple sclerosis
It is very uncertain whether rituximab as 'switching' changes mortality measured by clinical assessment over 12 months compared with placebo (very low certainty).
1 finding from 1 review
Clinical relapse · primary progressive multiple sclerosis
Rituximab as 'first choice' showed no clear difference in relapse measured by clinical assessment over 24 months compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events measured by clinical assessment over 12 months · primary progressive multiple sclerosis
Rituximab as 'first choice' showed no clear difference in serious adverse events measured by clinical assessment over 28 months compared with placebo (low certainty).
1 finding from 1 review
Subjective participant assessment at 4 weeks; 755 participants(6 RCTs) · cervical dystonia
Botulinum toxin type A leads to higher subjective participant assessment at 4 weeks; 755 participants(6 RCTs) compared with placebo (high certainty).
1 finding from 1 review
RR 2.19 [1.78, 2.7]
Studies not reported
High
Global state/functioning · men with alcohol dependency
1 finding from 1 review
Social functioning · adults with antisocial personality disorder
1 finding from 1 review
Reconviction (for drink‐driving) Assessed by: Cox regression of re‐arrest rates over 24 months Timing of assessment: 24 months · adults with antisocial personality disorder
It is very uncertain whether 'Driving whilst intoxicated' programme + incarceration changes reconviction (for drink‐driving) Assessed by: Cox regression of… compared with incarceration alone (very low certainty).
1 finding from 1 review
Reconviction · adults with antisocial personality disorder
It is very uncertain whether schema therapy changes reconviction Assessed by: number of participants documented to have… compared with treatment‐as‐usual (very low certainty).
1 finding from 1 review
Social functioning Assessed by: mean number of days until unsupervised leave grantedb Timing of assessment: over the 3 years · adults with antisocial personality disorder
1 finding from 1 review
Adverse events Assessed by: number of participants with a global negative outcome (e.g. dropping out of therapy, recidivism or being transferred to another facility due to poor treatment response) overall Timing of assessment: over the 3 years · adults with antisocial personality disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Social functioning · adults with antisocial personality disorder
1 finding from 1 review
Adverse events (self‐harm) Assessed by: mean number of self‐harm days in past 2 months Timing of assessment: 2 months · adults with antisocial personality disorder
1 finding from 1 review
Reconviction: total number of official offences recorded (higher number = worse outcome) Timing of the assessment: 1 year after release from prison · adults with antisocial personality disorder
1 finding from 1 review